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L iver cancer has a poor prognosis and has become the second leading cause of death due to malig-
nant neoplasms worldwide.  Transarterial chemoembo-
lization (TACE) is a standard treatment for intermedi-
ate stages of hepatocellular carcinoma (HCC) [1 , 2].  
The invasiveness of TACE is less than that of hepatec-
tomy,  but postembolization syndrome may be a prob-
lem [3].  During hepatocellular necrosis,  which is a 
main cause of postembolization syndrome,  alanine 
aminotransferase levels rise temporarily and abdominal 
pain and fever develop in a majority of HCC patients.  
Occasionally,  liver and splenic abscess,  acute cholecys-
titis,  and bile duct necrosis occur,  resulting in the 
development of ascites and hepatic encephalopathy,  
which are symptoms of hepatic failure.
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Steroids are often administered at the time of transcatheter arterial chemoembolization (TACE),  a standard 
treatment of hepatocellular carcinoma (HCC),  with the expectation of preventing postembolization syndrome.  
Here we investigated the precise effects of steroids on TACE.  We prospectively enrolled 144 HCC patients from 
10 hospitals who underwent TACE.  Three hospitals used steroids (steroid group,  n = 77) and the rest did not 
routinely use steroids (control group,  n = 67).  The occurrence of adverse events and the algetic degree at 1-5 
days post-treatment were compared between the groups.  Fever (grades 0-2) after TACE was significantly less in 
the steroid group (56/21/0) compared to the control group (35/29/3,  p= 0.005,  Cochran-Armitage test for 
trend).  The suppressive effect of steroids against fever was prominent in females (p= 0.001).  Vomiting (G0/G1/
G2-) was also less frequent in the steroid group (70/5/2) versus the control group (53/10/3),  but not signifi-
cantly (p= 0.106).  The algetic degree and the grade of hematological adverse events,  including hyperglycemia,  
did not differ between the groups.  We conclude that the administration of steroids was useful for the preven-
tion of adverse events after TACE in patients with HCC.
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In Japan,  gelatin sponge particles are frequently 
used as an embolic material [4].  Superselective TACE is 
usually performed to minimize damage to noncancer-
ous liver tissue and to maximize the effect of the treat-
ment,  but postembolization syndrome still frequently 
occurs.  There are no guidelines for the prevention of 
postembolization syndrome with preoperative and 
postoperative medications.
In daily practice,  nonsteroidal anti-inflammatory 
drugs (NSAIDs) and steroids are used empirically to 
relieve postembolization syndrome [5].  However,  the 
use of these drugs is the treating physician’s choice,  and 
protocols vary between institutions.  In addition,  the 
effects of steroid administration before and/or after 
TACE on the prevention of postembolization syndrome 
have not been demonstrated in detail,  and there are 
only a few reports dealing with this topic.
We conducted the present study to examine the util-
ity and safety of steroid use in the prevention of post-
embolization syndrome following TACE.
Patients and Methods
Patients. We conducted this prospective cohort 
study at Okayama University Hospital and 9 affiliated 
hospitals.  We enrolled HCC patients with a Child-Pugh 
score of A or B who underwent TACE from April 2013 
to December 2014.  The eligibility criteria were as fol-
lows: (i) the diagnosis of HCC was confirmed by means 
of histology or noninvasive criteria according to the 
European Association of the Study of the Liver or the 
American Association for the Study of Liver Diseases 
guidelines [1 , 6]; (ii) steroids or NSAIDs were not 
given regularly for underlying disease; (iii) the patient 
did not have uncontrolled diabetes mellitus; (iv) there 
was no allergy to contrast media; and (v) hepatic fail-
ure or renal failure was not found in a biochemical 
blood examination.
We defined the steroid group as the patients who 
were administered pre-treatment or post-treatment ste-
roids in the clinical protocol,  and we defined the 
patients without steroid administration as the control 
group.  The study profile is summarized in Fig. 1.  Of the 
158 patients enrolled,  14 patients were excluded because 
they did not follow the protocol.  Consequently,  77 
patients were enrolled in the steroid group,  and 67 
patients were enrolled in the control group.
We obtained informed consent from all patients who 
participated in this study.  The study protocol con-
formed to the ethical guidelines of the World Medical 
Association Declaration of Helsinki and was approved 
by the ethical committees of all institutions involved.
TACE procedure. TACE was performed accord-
ing to the clinical protocol of each institution.  The phy-
sicians who performed the procedures received training 
for a minimum of 2 years at Okayama University 
Hospital.  We performed selective TACE [7] whenever 
possible in both groups.  We used epirubicin (n = 110),  
doxorubicin (n = 14),  cisplatin (n = 8),  and miriplatin 
(n = 12) for the antineoplastic agent.  We used 1- or 
2-mm-diameter ready-made porous gelatin particles 
(Gelpart,  Nippon Kayaku,  Tokyo) in almost all cases 
for the embolic material.  No other invasive treatment 
for HCC was performed within 1 week after the TACE.
Steroid use. Three institutions used steroids rou-
tinely.  Hydrocortisone succinic acid ester sodium was 
used as the steroid at all institutions.  At institution 1 
(n = 54),  the patients were administered 100 mg of ste-
roid on days 1-3.  At institution 2 (n = 13),  300 mg of 
steroid was given on day 0 (before TACE).  At institu-
tion 3 (n = 10),  100 mg of steroid was given on days 
0-2.  Seven institutions did not routinely use steroids.  
Among those institutions,  NSAIDs were used on 
demand at six institutions,  and 100 mg naproxen was 
given orally twice daily on days 1-3 at one institution 
(n = 9).
Evaluation of adverse events. For all patients,  the 
severity of nausea,  vomiting,  and malaise were 
recorded,  corresponding to the Common Terminology 
Criteria for Adverse Events (CTCAE) [8] version 4.0 
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90 patients
from institutions which 
usually preloads steroids
72 patients enrolled
9 patients excluded for
periodical steroid internal use (n=3)
Child C (n=3) 
Periodical NSAIDs internal use (n=1)
pancytopenia (n=1)
Performance Status 3 (n=1)
4 patients excluded for 
Child C
86 patients enrolled
5 patients 
administrated steroids
9 patients didn’t 
administrate steroids
Steroid group:
77 patients
Control group:
67 patients
81 patients
from institutions which does 
not usually preloads steroids
Fig. 1　 Flow chart of patient enrollment.
grade and based on a numeric rating scale (NRS) from 
0 to 10 indicating the degree of pain on a daily ques-
tionnaire from before the treatment to 5 days after the 
treatment.  We also examined the grade of fever before 
TACE to 5 days after TACE.
The primary endpoint was the grade of nausea,  
vomiting,  fever,  and malaise observed during the study 
period and the emergence of other adverse events asso-
ciated with TACE.  The secondary endpoint was the 
degree and duration of pain due to TACE.
Statistical analysis. We used t-tests for continu-
ous data and chi-square tests,  Fisher’s exact tests,  and 
Cochran-Armitage’s tests for trends in categorical data.  
For the evaluation of nausea,  vomiting,  fever,  and 
malaise,  we calculated the incidence according to grade 
on each observation day.  We calculated a maximum 
pain score and a cumulative pain score during the 
period of observation and then performed a t-test 
between the two groups.  We compared the incidence of 
an NRS rating of ≥ 1 between the 2 groups on each 
observation day,  as well as the number of days with an 
NRS rating of ≥ 1 between the 2 groups.  We used JMP 
Pro 12.0.1 software (SAS Institute,  Cary,  NC,  USA) for 
our statistical analyses.
Sample size estimation. Prior to this study,  we 
performed 17 TACEs with and without steroids and 
evaluated the postembolization syndrome.  We calcu-
lated that 66 cases per group were necessary to deter-
mine whether steroid use decreases the incidence of 
fever by one-half.  We planned to enroll 75 cases in each 
group,  with the prospect of a 10% dropout rate.
Results
Patient characteristics. The patients’ background 
factors are indicated in Table 1.  There were more ascitic 
fluid cases in the steroid group,  while the control group 
had more diabetes cases.  Significant differences in 
characteristics were not observed between the steroid 
and control groups.  There were no patients with severe 
diabetes showing glycated hemoglobin (HbA1c) > 8.5%.
Symptoms. The incidence of each grade of fever,  
vomiting,  nausea,  malaise,  and other adverse symp-
tom events is provided in Table 2.  The grade of fever in 
the steroid group was significantly lower than that in the 
control group (p = 0.005).  The grade of vomiting after 
TACE in the steroid group tended to be lower than that 
in the control group (p= 0.106).  For nausea and malaise,  
there were no differences in their grade after TACE 
between the groups.  In addition,  extravasation at the 
infusion site was found in the steroid group,  and stom-
ach pain,  hepatic failure,  pleural effusion,  and head-
ache were recorded in the control group.  These adverse 
symptoms occurred in small numbers,  and thus a sta-
tistical examination was not performed.
Because fever,  vomiting,  nausea,  malaise,  and pain 
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Table 1　 Baseline characteristics of the patients
Steroid Group (n=77) Control Group (n=67) P-value
Background Factors
　Age (years) 73 (45-87) 74 (39-92) 0.359
　Male (n) 50 (65%) 43 (64%) 1.000
　Body Mass Index 22.2 (16.7-33.5) 22.3 (16.7-29.9) 0.921
　Performance Status 0 66 (86%) 56 (85%)
1 11 (14%) 10 (15%) 1.000
　Total bilirubin (mg/dL) 1.0 (0.4-2.4) 0.8 (0.3-3.0) 0.835
　Serum albumin (g/dL) 3.5 (2.4-4.6) 3.6 (2.5-4.9) 0.235
　Ascites (present) 24 (31%) 11 (16%) 0.051
　Hepatic encephalopathy (present) 3 (4%) 4 (6%) 0.705
　Prothrombin time (%) 92 (41-123) 88 (40-133) 0.685
　Child-Pugh Grade A 51 (66%) 50 (75%)
B 26 (34%) 17 (25%) 0.362
　Diabetes (present) 15 (19%) 23 (34%) 0.058
Tumor Related Factors
　Main tumor size (mm) 20 (7-127) 21 (9-97) 0.443
　Tumor number (single) 28 (36%) 19 (28%) 0.374
Values are median (range) unless otherwise noted.
were frequently observed as adverse events of TACE and 
effects of the steroids were expected,  we evaluated these 
chronologically (Fig. 2a-e).  Fever was most frequently 
observed on days 1 and 2 in the control group,  while 
the incidence was significantly lower in the steroid 
group (days 1 and 3).  The incidence was decreased 
almost to the baseline level on day 4 in both groups.  
When we analyzed the effect in different genders,  there 
were no significant differences at any time points for the 
men,  whereas a significant difference was found in the 
women on days 1 (p = 0.009) and 2 (p = 0.023) (Fig. 2a).
The frequencies of vomiting,  nausea,  and malaise 
were highest on day 1 and returned to the baseline on 
day 5.  Vomiting was less frequent in the steroid group 
on day 2,  but this difference was also observed before 
TACE (Fig. 2b).  No difference in the frequency of nau-
sea or malaise was observed between the steroid and 
control groups throughout the observation period 
(Fig. 2c , d).
For our analysis of pain,  we excluded cases that 
showed an NRS rating of ≥ 2 before TACE to avoid the 
effect of pain that was unrelated to the treatment.  The 
maximum NRS rating was 2.9 ± 2.6 (mean ± standard 
deviation) in the steroid group and 2.1 ± 2.6 in the con-
trol group; this difference was not significant 
(p = 0.116).  The sum of NRS ratings from day 1 to day 5 
was 5.8 ± 7.3 in the steroid group and 5.8 ± 8.7 in the 
control group (p = 0.977).  For pain,  we evaluated the 
frequency of an NRS rating of ≥ 2 chronologically;  
there were no significant differences between the two 
groups at any time point (Fig. 2e).
The body weights of the women were lower than 
those of the men,  and to determine whether the differ-
ence in body weight was the reason for the gender dif-
ferences in the effects of steroids on fever,  we con-
ducted a subanalysis for a group (33 men,  33 women) 
whose body weights matched at 1 : 1.  The differences in 
fever incidence between the male and female groups 
from days 1 to 3 were still significant in this matched 
group of women (11% vs. 27% on day 1,  6% vs. 27% on 
day 2,  and 6% vs. 29% on day 3 in the steroid group vs. 
the control group).  This result suggests that the gender 
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Table 2　 Adverse events observed after TACE
Steroid Group (n=77) Control Group (n=67) P-value
G0 G1 G2 G3 G4 G0 G1 G2 G3 G4
Symptoms AEs
　Nausea 44 (58) 22 (29) 8 (10) 2 (3) 42 (64) 13 (20) 7 (10) 4 (6) 0.933
　Vomiting 70 (91) 5 (6) 2 (3) 0 (0) 0 (0) 53 (80) 10 (15) 3 (5) 0 (0) 0 (0) 0.106
　Fever 56 (73) 21 (27) 0 (0) 0 (0) 0 (0) 35 (52) 29 (43) 3 (5) 0 (0) 0 (0) 0.005
　Malaise 20 (26) 40 (52) 17 (22) 25 (38) 30 (45) 11 (17) 0.143
　Infusion site extravasation 1 (1)
　Stomach pain 1 (1)
　Hepatic failure 1 (1) 1 (1)
　Pleural eﬀusion 1 (1)
　Headache 1 (1) 1 (1)
Hematologic AEs
　ALP increased 73 (95) 4 (5) 0 (0) 0 (0) 0 (0) 65 (97) 2 (3) 0 (0) 0 (0) 0 (0) 0.508
　ALT increased 32 (42) 27 (35) 7 (9) 11 (14) 0 (0) 26 (40) 25 (37) 6 (9) 9 (13) 1 (1) 0.760
　AST increased 30 (39) 10 (13) 21 (27) 16 (21) 0 (0) 25 (38) 14 (21) 14 (21) 13 (19) 1 (1) 0.880
　Hypoalbuminemia 27 (35) 21 (27) 28 (37) 1 (1) 0 (0) 27 (40) 19 (29) 20 (30) 1 (1) 0 (0) 0.437
　Creatinine increased 71 (92) 6 (8) 0 (0) 0 (0) 0 (0) 62 (93) 5 (7) 0 (0) 0 (0) 0 (0) 0.941
　Anemia 54 (70) 12 (16) 11 (14) 0 (0) 0 (0) 52 (78) 4 (6) 9 (13) 2 (3) 0 (0) 0.856
　Blood bilirubin increased 38 (49) 22 (29) 17 (22) 0 (0) 0 (0) 35 (52) 23 (35) 8 (12) 1 (1) 0 (0) 0.440
　Neutrophil count decreased 75 (97) 2 (3) 0 (0) 0 (0) 0 (0) 63 (94) 3 (5) 1 (1) 0 (0) 0 (0) 0.262
　WBC decreased 68 (88) 5 (7) 3 (4) 1 (1) 0 (0) 56 (84) 2 (3) 6 (9) 3 (4) 0 (0) 0.164
　Platelet count decreased 60 (78) 4 (5) 10 (13) 3 (4) 0 (0) 46 (69) 6 (9) 10 (15) 5 (7) 0 (0) 0.237
　Hyperglycemia 56 (73) 17 (22) 4 (5) 0 (0) 0 (0) 52 (78) 13 (19) 2 (3) 0 (0) 0 (0) 0.430
AE,  adverse event; ALP,  alkaline phosphatase; ALT,  alanine aminotransferase; AST,  aspartate aminotransferase; WBC,  white blood 
cell.  Values in parentheses are percentages.  All statistical analyses were by the Cochran-Armitage test for trend.
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Fig. 2　 The degree of adverse events before and after TACE.  A gender-speciﬁc 
diﬀerence was observed for fever.  Solid line: The steroid group.  Dashed line:  
The control group.  ＊A signiﬁcant diﬀerence in incidence between groups at that 
time point.
differences observed in the steroid effect were not due to 
the difference in body weight.
We conducted a subanalysis in the steroid group,  
and all adverse events except malaise were not signifi-
cantly different among the 10 institutions.  The inci-
dence of malaise was low in 2 institutions where ste-
roids were administered after TACE.
Hematological disorders. We compared 11 
adverse hematological events (Table 2).  There were no 
significant differences in the incidence of these events 
between the steroid and control groups.  No patients in 
either group showed hyperglycemia over grade 2 after 
TACE.
Severe adverse events. Only one serious adverse 
event (pleural effusion) was reported in the control 
group.  The patient was an 85-year-old male with multi-
ple HCCs (maximum tumor diameter 27 mm),  and his 
Child-Pugh score was 5 (Child-Pugh grade A).  TACE 
using a 6.3-ml epirubicin emulsion was performed to 
A7,  A8,  and the lower right phrenic artery.  The pleural 
effusion appeared 2 days after the treatment,  and the 
patient’s respiratory status worsened.  An albumin infu-
sion and oxygenation relieved the respiratory status.  We 
confirmed the disappearance of pleural effusion by 
computed tomography on the 36 th day after TACE.
Discussion
In the steroid group,  the incidence of fever was sig-
nificantly lower than in the control group at 1 to 3 days 
after TACE.  This tendency was particularly strong 
among the women.  The incidence of vomiting in the 
steroid group also tended to be low,  but no significant 
differences were found in nausea,  malaise,  or pain 
incidence between the groups.  The risks of hyperglyce-
mia and infection have been reported to increase with 
perioperative steroid administration [9].  However,  we 
observed no significant differences in the incidence of 
adverse hematological events,  including hyperglyce-
mia,  between the present steroid and control groups.  In 
addition,  we did not observe any other disadvantages 
associated with steroid administration.
When tumor tissue and the neighboring liver paren-
chyma are embolized by TACE,  many cytokines and 
prostaglandin are produced,  resulting in inflammation.  
Though selective TACE has become common in Japan 
for reducing postembolization syndrome,  undesired 
effects can not be avoided.  Steroids block the effects of 
factors causing inflammation and suppress the function 
of leukocytes that elevate inflammation.  The incidence 
of fever after TACE in the steroid group of the present 
study might have been reduced by this anti-inflamma-
tory function of steroids.  However,  few studies have 
been conducted because of the difficulty in unifying the 
procedures of TACE.  In addition,  many physicians are 
wary of increasing their patients’ risk of infection and/
or exacerbating hepatitis by the use of a steroid.
Steroids are widely used to prevent the nausea 
caused by anticancer drugs.  In particular,  dexametha-
sone,  a strong and long-acting steroid,  is used for 
anti-nausea purposes prior to the administration of 
various anticancer drugs [10-13].  Ho et al.  reported that 
dexamethasone prevents nausea and vomiting after sur-
gery [9].  In the present study,  we examined the differ-
ences in the incidence of nausea and vomiting after 
TACE in the presence or absence of steroids.  The inci-
dence of vomiting was significantly lower in the steroid 
group,  but the incidence of vomiting was already high 
before treatment in the control group.  Therefore,  we 
were not able to determine the effect of steroids on 
vomiting.
We used hydrocortisone succinic acid ester sodium,  
a short-acting steroid,  to suppress inflammation after 
TACE.  The incidence of nausea and vomiting may have 
been further decreased if a long-acting steroid had been 
used in this patient series.  However,  it is difficult to use 
strong,  long-acting steroids for the purpose of relieving 
acute inflammation caused by TACE because many of 
the patients suffer from viral hepatitis.  The exacerba-
tion of hepatitis caused by the withdrawal of a steroid is 
sometimes dangerous,  especially for cirrhotic patients 
with hepatitis B virus infection.  In addition,  it was 
reported that the side effects of steroids,  such as gastro-
intestinal mucous membrane disorder,  hyperglycemia,  
and psychic disturbance,  occur more readily in strong 
steroid users [9].  Infection at the embolic site is another 
concern.
When we examined the post-treatment effect of ste-
roids on fever,  differences were revealed between the 
sexes in a gender-related subanalysis.  There is reported 
evidence suggesting that gender is an important factor 
in pain modulation.  According to Pueretti et al.  [14],  
modulation of the endogenous opioid system and sex 
hormones are factors that influence pain sensitivity in 
males and females.  We have found no reports about 
gender differences in the effects of steroids on fever;  
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this phenomenon might have happened by chance.
A similar study was reported by Kogut et al.  [15].  
They compared the requirements for narcotic and anti-
emetic medications after TACE for HCC among three 
patient groups with differing dexamethasone adminis-
tration regimens.  Their results support our finding that 
vomiting after TACE is decreased by steroid adminis-
tration.  However,  we cannot directly compare the 
Kogut study with our present investigation because 
their study evaluated the degree of symptoms of patients 
based on drug consumption,  not on a rating scale.
Our study does have limitations.  First,  the TACE 
procedure was considered to be equal between the 
treatment groups,  but our study was not a randomized 
controlled trial,  so we cannot rule out the influence of 
technical differences.  Second,  the number of patients 
was not large enough to detect small differences in mul-
tiple adverse events.  Third,  the protocol for the steroid 
administration was not unified among the institutions.
Despite these limitations,  the results of our analyses 
clearly demonstrated that steroid treatment before and 
after TACE for HCC was safe,  and that it was useful for 
relieving postoperative fever.  The effect seemed to be 
stronger in women than in men,  but this needs further 
investigation.
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